Th heart disease treatment developer has secured $248m in funding since being formed to exploit UT Southwestern and Gladstone Institute research.

Tenaya Therapeutics, a US-based developer of therapies for heart disease based on Gladstone Institutes and University of Texas Southwestern Medical Center research, has filed for an initial public offering. The company intends to float on the Nasdaq Stock Market and set a $100m placeholder target for the offering. Tenaya is developing treatments utilising cellular regeneration,…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.